Spots Global Cancer Trial Database for head and neck
Every month we try and update this database with for head and neck cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | NCT04534205 | Unresectable He... Metastatic Head... Recurrent Head ... | BNT113 Pembrolizumab | 18 Years - | BioNTech SE | |
| Changes in Body Composition After EPA Supplementation in Head and Neck Patients | NCT02715596 | Squamous Cell C... | EPA supplementa... Placebo | 18 Years - | Institut Català d'Oncologia | |
| A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer | NCT01744340 | Head and Neck C... Colon Cancer | Head and neck Colon- Closed a... | 18 Years - | Brown University | |
| Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck | NCT03708224 | Cancer Carcinoma Squamous Cell C... Head and Neck C... | Atezolizumab Tocilizumab Tiragolumab | 18 Years - | University of California, San Francisco | |
| Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN) | NCT04606940 | Head and Neck C... Advanced Cancer Metastatic Canc... HNSCC Squamous Cell C... | 18 Years - | University Health Network, Toronto | ||
| A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors | NCT02605083 | Cancer | eFT508 | 18 Years - | Effector Therapeutics | |
| International Cancer of the Head and Neck, Genetics and Environment (InterCHANGE) Study | NCT01972802 | Evaluate the As... Assess the Effe... | 18 Years - 80 Years | National Taiwan University Hospital | ||
| Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck | NCT00848042 | Head and Neck C... | AuroLase Therap... | 18 Years - 130 Years | Nanospectra Biosciences, Inc. | |
| A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer | NCT00735826 | Aerodigestive T... Lung Cancer Esophageal Canc... Head and Neck C... | Vorinostat | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Pembrolizumab Plus Olaparib in LA-HNSCC | NCT05366166 | Squamous Cell C... | Pembrolizumab Olaparib Cisplatin IMRT (intensity... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer | NCT00176267 | Squamous Cell C... | Radiotherapy Paclitaxel Carboplatin | 18 Years - | University of Kentucky | |
| Nutritional Status and Barriers to Dietary Intake in Head and Neck Cancer Patients | NCT00375180 | Head and Neck C... | 18 Years - | AHS Cancer Control Alberta | ||
| The Head and Neck Tumor Biobank | NCT01644786 | Head and Neck S... | 18 Years - | Maastricht Radiation Oncology | ||
| Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer | NCT02777385 | Head and Neck S... | Pembrolizumab Cisplatin IMRT | 18 Years - | University of Pittsburgh | |
| Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN | NCT03529422 | Larynx Lip Oral Cancer Digestive Organ... | Durvalumab Intensity Modul... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | NCT04044859 | Endometrial Can... Esophageal Canc... Esophagogastric... Gastric (Stomac... Head and Neck C... Melanoma Ovarian Cancer Non-small Cell ... Urothelial Canc... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT02035527 | Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Oral ... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas... | sorafenib tosyl... cisplatin docetaxel Correlative Stu... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck | NCT02236936 | Squamous Cell C... Squamous Cell C... Laryngeal Squam... Laryngeal Squam... Oropharyngeal S... Oropharyngeal S... Squamous Cell C... Squamous Cell C... Locally Advance... | Standard care o... Parenteral over... Cetuximab Cisplatin Radiotherapy | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| PentoxIfylline and Tocopherol for the Treatment of Post-radiotherapy Fibrosis in Head and Neck Cancer Patients | NCT03723291 | Head and Neck F... | Arm B: A combin... • Arm A: Best s... | 18 Years - | University College, London | |
| Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck | NCT01491139 | Carcinoma, Squa... | olaparib cisplatin Intensity Modul... | 18 Years - | University College, London | |
| Study of HLA-DR in Cell Cultures Isolated From Primary Squamous Cell Carcinoma | NCT06041464 | Squamous Cell C... Cancer | cell culture | - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Changes in Body Composition After EPA Supplementation in Head and Neck Patients | NCT02715596 | Squamous Cell C... | EPA supplementa... Placebo | 18 Years - | Institut Català d'Oncologia | |
| Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer | NCT00661427 | Head and Neck Squamous Cell C... | cetuximab cetuximab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer | NCT00131638 | Head and Neck C... | Placebo Palifermin | 18 Years - | Amgen | |
| A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer | NCT00131638 | Head and Neck C... | Placebo Palifermin | 18 Years - | Amgen | |
| ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma | NCT01218048 | Squamous Cell C... | Cetuximab Surgery Post-surgical r... Cisplatin or ca... | 18 Years - | University of Pittsburgh | |
| ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer | NCT05182866 | Head and Neck C... Squamous Cell C... | ASP-1929 Photoi... | 18 Years - | Rakuten Medical, Inc. | |
| A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer | NCT01744340 | Head and Neck C... Colon Cancer | Head and neck Colon- Closed a... | 18 Years - | Brown University | |
| Investigation of the Role of Human Papilloma Virus (HPV) in the Prognosis of Head and Neck Cancer | NCT02049177 | Head and Neck C... | 18 Years - | University of Aberdeen | ||
| Pilot Study to Evaluate Photoacoustic Imaging in Head and Neck Cancer | NCT04428515 | Head and Neck C... | Photoacoustic I... | - | Sunnybrook Health Sciences Centre | |
| The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound | NCT00813631 | Head and Neck N... Head and Neck C... Wounds Ulcer | silver-releasin... | 18 Years - | National Taiwan University Hospital | |
| Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study. | NCT01173692 | Oropharynx Canc... | Minocycline Placebo | 18 Years - | M.D. Anderson Cancer Center | |
| Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04892043 | Adult Solid Tum... | SQZ-AAC-HPV Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
| Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | NCT03301896 | Solid Tumors | LHC165 PDR001 | 18 Years - | Novartis | |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | NCT03841110 | Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small Cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car... | FT500 Nivolumab Pembrolizumab Atezolizumab Cyclophosphamid... Fludarabine IL-2 | 18 Years - | Fate Therapeutics | |
| Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients | NCT00437372 | Cancer Head and Neck C... Pelvic Cancer Nervous System ... Thoracic Neopla... | Sunitinib External Beam R... | 18 Years - | Thomas Jefferson University | |
| ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases | NCT05265013 | Head and Neck C... | ASP-1929 Photoi... | 20 Years - | Rakuten Medical, Inc. | |
| A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer. | NCT01606566 | Recurrent Head ... Carcinoma, Squa... | Amphinex induce... | 18 Years - | PCI Biotech AS | |
| Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma | NCT04599309 | Cancer Head and Neck S... Head and Neck C... | 18 Years - | University Health Network, Toronto | ||
| A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors | NCT02605083 | Cancer | eFT508 | 18 Years - | Effector Therapeutics | |
| A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer | NCT02901483 | Head and Neck S... | PEP503 Cisplatin Radiotherapy | 20 Years - | PharmaEngine | |
| The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer | NCT01706939 | Squamous Cell C... | Reduced Dose Ra... Standard Dose R... Carboplatin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma | NCT06332092 | Head and Neck S... | FID007 | 18 Years - | Fulgent Pharma LLC. | |
| Oxygen Enhanced MRI Measurement in Head and Neck Cancer: Validation and Efficacy of Response. | NCT03646747 | Head and Neck C... | MRI scan | 18 Years - | The Christie NHS Foundation Trust | |
| A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer | NCT04405154 | Head and Neck N... | Camrelizumab Cisplatin IMRT or VMAT | 18 Years - 75 Years | West China Hospital | |
| Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN | NCT03529422 | Larynx Lip Oral Cancer Digestive Organ... | Durvalumab Intensity Modul... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy | NCT00540332 | Head and Neck C... | Placebo palifermin | 18 Years - | Swedish Orphan Biovitrum | |
| Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | NCT03383094 | Head and Neck S... Cancer Cancer of Head ... Cancer, Advance... Cancer, Metasta... Tumor Tumor Recurrenc... Tumor Neck Tumor Metastasi... Oral Cancer Oropharyngeal C... Oropharynx Canc... Oropharynx Canc... Oropharynx Canc... Oropharynx Canc... | Pembrolizumab Radiation thera... Cisplatin | 18 Years - | University of California, San Diego | |
| Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck | NCT01275183 | Head and Neck C... | raltegravir and... | 18 Years - | New Mexico Cancer Care Alliance | |
| A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer | NCT00131638 | Head and Neck C... | Placebo Palifermin | 18 Years - | Amgen | |
| Phase 1 and 2 Study of PX-866 and Cetuximab | NCT01252628 | Incurable Metas... Incurable Progr... | PX-866 (SCCHN) Cetuximab (SCCH... PX-866 (CRC) Cetuximab (CRC) | 18 Years - | Seagen Inc. | |
| Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04892043 | Adult Solid Tum... | SQZ-AAC-HPV Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
| Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease | NCT04685499 | Head and Neck S... | OBP-301 Pembrolizumab | 18 Years - | Weill Medical College of Cornell University | |
| ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy | NCT03769506 | Head and Neck C... | ASP-1929 Photoi... Physician's Cho... | 18 Years - | Rakuten Medical, Inc. | |
| Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04084951 | Adult Solid Tum... | SQZ-PBMC-HPV Atezolizumab Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
| Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients | NCT00437372 | Cancer Head and Neck C... Pelvic Cancer Nervous System ... Thoracic Neopla... | Sunitinib External Beam R... | 18 Years - | Thomas Jefferson University | |
| Advanced MRI Sequences for Radiation Therapy Treatment Planning | NCT02340715 | Cancer | 18 Years - 89 Years | Medical College of Wisconsin | ||
| Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck | NCT02236936 | Squamous Cell C... Squamous Cell C... Laryngeal Squam... Laryngeal Squam... Oropharyngeal S... Oropharyngeal S... Squamous Cell C... Squamous Cell C... Locally Advance... | Standard care o... Parenteral over... Cetuximab Cisplatin Radiotherapy | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients | NCT00437372 | Cancer Head and Neck C... Pelvic Cancer Nervous System ... Thoracic Neopla... | Sunitinib External Beam R... | 18 Years - | Thomas Jefferson University | |
| Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients | NCT01941992 | Head-and-neck S... Oral Mucositis | SAMITAL® Placebo sachets | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| SCRI Tissue Testing Registry | NCT00965861 | Melanoma Myelodysplastic... Multiple Myelom... Lymphoma | Tissue Registry... | 18 Years - | SCRI Development Innovations, LLC | |
| High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS) | NCT04126460 | Head and Neck C... | Toripalimab | 18 Years - | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| The Head and Neck Tumor Biobank | NCT01644786 | Head and Neck S... | 18 Years - | Maastricht Radiation Oncology | ||
| The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer | NCT01706939 | Squamous Cell C... | Reduced Dose Ra... Standard Dose R... Carboplatin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab | NCT01436617 | Colon Cancer Head and Neck C... Allergic Reacti... | blood sample | 18 Years - | Centre Francois Baclesse | |
| Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer | NCT00176267 | Squamous Cell C... | Radiotherapy Paclitaxel Carboplatin | 18 Years - | University of Kentucky | |
| Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors | NCT03684785 | Advanced or Met... Advanced or Met... Advanced or Met... Advanced or Met... Advanced or Met... | Cavrotolimod Pembrolizumab Cemiplimab Cavrotolimod | 18 Years - | Exicure, Inc. | |
| A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) | NCT03861793 | Advanced Solid ... | ALKS 4230 Pembrolizumab | 18 Years - | Mural Oncology, Inc | |
| Value of Geriatric Screening to Predict Postoperative Morbidity for Head and Neck Cancer | NCT03053310 | Head and Neck | 70 Years - | AZ Sint-Jan AV | ||
| Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design | NCT02128906 | Squamous Cell C... | Cisplatin IMRT Docetaxel Cetuximab | 18 Years - | University of Pittsburgh | |
| A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors | NCT01963715 | EGFR Positive S... | IMGN289 | 18 Years - | ImmunoGen, Inc. | |
| Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer | NCT01247246 | Oral Mucositis | SCV-07 Placebo | 18 Years - | SciClone Pharmaceuticals | |
| Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT00547157 | Cancer Head and Neck C... Oncology Squamous Cell C... | Panitumumab Cisplatin | 18 Years - | Amgen | |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | NCT05199584 | Solid Tumors Wi... | ENV-101 (talade... | 18 Years - | Endeavor Biomedicines, Inc. | |
| Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer | NCT03268993 | Head and Neck C... Head and Neck S... Head and Neck C... Head and Neck Tobacco-Related... Carcinoma in Si... Dysplasia Hyperplasia Premalignant Le... | Avmacol | 18 Years - | University of Pittsburgh | |
| FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma | NCT06332092 | Head and Neck S... | FID007 | 18 Years - | Fulgent Pharma LLC. | |
| The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer | NCT01706939 | Squamous Cell C... | Reduced Dose Ra... Standard Dose R... Carboplatin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients | NCT01941992 | Head-and-neck S... Oral Mucositis | SAMITAL® Placebo sachets | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck | NCT01332266 | Platinum-Resist... | E7050 Cetuximab | 18 Years - | Eisai Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
